|Bid||24.80 x 900|
|Ask||24.84 x 3200|
|Day's Range||24.58 - 25.36|
|52 Week Range||1.94 - 28.00|
|Beta (3Y Monthly)||2.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.00|
Investors seeking stocks with high reward potential might want to consider this pharmaceutical company, oil and gas driller, and wind blade maker instead of wading into the high-risk penny stock market.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 1) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arena Pharmaceuticals, ...
Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has been added to the Russell 3000® and Russell 2000® Indexes, as part of the annual Russell indexes reconstitution, which took place following the US market close on June 28, 2019. The Russell indexes are rebalanced each June in order to capture growing equities and market changes that occurred in the preceding year. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Hedge funds and other investment firms that we track manage billions of dollars of their wealthy clients' money, and needless to say, they are painstakingly thorough when analyzing where to invest this money, as their own wealth also depends on it. Regardless of the various methods used by elite investors like David Tepper and David […]
Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, enrolled the first patient in its GEMINI (Glutamatergic and Monoaminergic Modulation in Depression) study, a Phase 3, randomized, double-blind, placebo-controlled trial of AXS-05 in the treatment of major depressive disorder (MDD). AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity.
Placebo-controlled Phase 3 trial of AXS-05 in MDD on track to start in 2Q 2019 Topline results from both STRIDE-1 Phase 3 trial in TRD and planned placebo-controlled Phase 3.
A look at the shareholders of Axsome Therapeutics, Inc. (NASDAQ:AXSM) can tell us which group is most powerful...
NEW YORK, May 21, 2019 -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous.
This startup has rapidly developed two potential blockbusters that are close to the finish line, and hardly anybody's noticed yet.
On a per-share basis, the New York-based company said it had a loss of 32 cents. Axsome shares have increased sixfold since the beginning of the year. The stock has risen fivefold in the last 12 months. ...
Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2019. “The first five months of 2019 have been highly productive at Axsome as we advanced our mission to develop innovative medicines for patients living with serious and difficult-to-treat CNS disorders. “We also received Breakthrough Therapy designation from the FDA for AXS-05 for the treatment of major depressive disorder, and recently announced, based on the Breakthrough Therapy meeting, an expedited clinical development plan for AXS-05 in depression which could result in a potential NDA filing for AXS-05 in 2020.
Axsome Therapeutics Inc. (AXSM) gained 39 cents to $19.54 on Tuesday on 1.4 million shares traded. The biotech company announced Monday that the FDA granted breakthrough therapy designation for a major depressive disorder treatment. It’s now right at lateral resistance, a break through which could lead to the $20 range short-term.
Here are four stocks to watch with strong technical momentum fueled by earnings and other news. Axsome Therapeutics, Inc. (NASDAQ: AXSM ) gained 39 cents to $19.54 on Tuesday on 1.4 million shares. The ...
Fuel Tech's (FTEK) Q1 results are likely to benefit from increased adoption of emission control solutions, efforts to improve sales channel and addition of a coal-fired unit in the United States.
On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.